AI Consensus Investment Thesis
Natera (NTRA) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
PARTIAL SELL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
SELL ALL$323
-12.6%5-Year
PARTIAL SELL$362
-2.1%Latest flagship insight
Clinical Monopoly Encounters Valuation Gravity Amid Elevating Cost Of Capital
A sharp divergence defines the outlook: high consensus affirms Signatera's rapid clinical adoption and expanding gross margins, yet deep disagreement surrounds valuation durability. At twenty times sales in a high-rate regime, multiple contraction threatens to neutralize volume growth unless genuine operating profitability materializes.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Universal Investor (Polymath), Ray Dalio (Strategist), Machiavelli (Insider), Warren Buffett (Value Purist), Superintelligence (Anthropologist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower), J.P. Morgan (Titan), Elon Musk (Visionary). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Natera at the forecast anchor (2026-09-18): $9,789 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 346.91 | -6.09% | -6.09% | Persistent 5% Treasury yields induce multiple compression across high-valuation diagnostics, dampening equity performance despite robust Q3 Signatera test volumes and solid operational execution. |
| Q1 2027 | 332.01 | -4.30% | -10.12% | Full-year 2026 disclosures confirm top-line growth near $2.9 billion, but continuing GAAP operating deficits and heavy 2027 R&D budgets prompt institutional multiple adjustments. |
| Q2 2027 | 338.43 | +1.93% | -8.38% | Expanded Medicare MolDX indications in oncology surveillance lift realized average selling prices, sparking a tactical relief rally supported by gross margins holding above 65%. |
| Q3 2027 | 322.92 | -4.58% | -12.58% | Private commercial health insurers intensify prior-authorization friction across molecular panels, slowing sequential cash collections and reigniting multiple compression across high-beta medical technology. |
| Q4 2027 | 327.63 | +1.46% | -11.30% | Encouraging early cancer detection cohort readouts and expanded guideline inclusion in breast cancer provide sentiment support, offsetting tax-loss selling into year-end. |
| Q1 2028 | 321.58 | -1.85% | -12.94% | Initial 2028 guidance indicates research spending growth is beginning to moderate relative to sales, though elevated cost-of-capital hurdles keep valuation multiples restrained. |
| Q2 2028 | 325.50 | +1.22% | -11.88% | Laboratory sequencing automation and rising test density lower per-sample costs, lifting unit contribution margins and driving positive operational cash flow expansion. |
| Q3 2028 | 326.92 | +0.44% | -11.50% | International commercialization in Japan under PMDA reimbursement provides geographic diversification, helping balance competitive pricing noise from rival tumor-naive assay launches. |
| Q4 2028 | 325.30 | -0.50% | -11.93% | Resolution of outstanding false-advertising litigation liabilities and diagnostic fee schedule reviews introduces brief headline drag, followed by fundamental balance-sheet stabilization. |
| Q1 2029 | 329.73 | +1.36% | -10.74% | Fiscal 2028 filings demonstrate the first sustained approach to GAAP operating breakeven, broadening institutional interest among quality-oriented healthcare funds. |
| Q2 2029 | 335.39 | +1.71% | -9.21% | Updated pan-cancer guideline endorsements expand the addressable surveillance cohort, generating steady sequential accession growth and reinforcing Signatera's clinical standard-of-care moat. |
| Q3 2029 | 334.94 | -0.13% | -9.33% | Commercial payer contract renewals enforce modest pricing concessions on serial testing, keeping forward price-to-sales multiples anchored to mature diagnostic industry baselines. |
| Q4 2029 | 340.20 | +1.57% | -7.90% | Biopharmaceutical companion diagnostic partnerships deliver milestone and royalty payments, strengthening working capital and supporting share valuation through year-end. |
| Q1 2030 | 340.85 | +0.19% | -7.73% | Annual revenue crosses $4.8 billion with verifiable GAAP profitability, marking the formal corporate transition from speculative growth asset to mature medical utility. |
| Q2 2030 | 345.43 | +1.34% | -6.49% | Expanding commercial coverage across community oncology practices drives test volume scale, while higher throughput cushions against lingering industry reimbursement scrutiny. |
| Q3 2030 | 346.02 | +0.17% | -6.33% | Rival next-generation liquid biopsy platforms intensify competitive bidding for hospital laboratory contracts, producing moderate pricing headwinds that check multiple expansion. |
| Q4 2030 | 350.77 | +1.37% | -5.04% | Sustained annual free cash flow exceeding $400 million provides strategic flexibility, enabling potential share buybacks to mitigate executive stock-based compensation dilution. |
| Q1 2031 | 353.61 | +0.81% | -4.27% | Consolidated 2030 results confirm durable double-digit top-line compounding and solid margins, establishing a stable fundamental foundation for the equity. |
| Q2 2031 | 359.70 | +1.72% | -2.62% | Maturing domestic oncology surveillance is augmented by expanding international diagnostic demand, maintaining steady cash generation across diversified disease indications. |
| Q3 2031 | 361.59 | +0.52% | -2.11% | The five-year scenario concludes with the enterprise fully transitioned into a profitable diagnostics compounder, where robust operational growth has absorbed multiple normalization. |
The base-case economic thesis centers on an acute divergence between operational compounding and equity duration sensitivity. Clinically, Signatera is solidifying standard-of-care status in oncology molecular residual disease, where longitudinal surveillance protocols convert episodic tests into high-visibility recurring volume. Combined with reproductive screening cash flows and sequencing automation, enterprise revenue is set to scale from $2.71 billion toward $6.0 billion by 2031 with gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry above 65%. However, equity pricing at nearly twenty times revenue in a 5% sovereign yield environment discounts flawless execution while ignoring structural capital costs. Trailing free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry of $71.7 million against a $53 billion market capitalizationmarket capitalizationThe market value of an asset or company, commonly calculated for a company as share price multiplied by shares outstanding.View full glossary entry reflects heavy reliance on stock-based compensation add-backs. As top-line growth decelerates toward 20%, multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry toward high single-digit sales multiples will absorb operational gains, leaving equity returns modest.
Key insights
- Longitudinal surveillance transforms diagnostic testing into a recurring subscription-like revenue engine, yet realized ASP expansion faces intensifying resistance from private commercial payers.
- Intangible research commitments exceeding $800 million annually build defensible clinical evidence moats but defer statutory GAAP net earnings well into late 2028.
- DilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry from equity incentives and contingent legal liabilities from false-advertising verdicts reduce the per-share economic value captured by public equity holders.
Natera is expanding rapidly as doctors increasingly rely on its Signatera test to detect cancer recurrence early. This clinical success and steady prenatal testing are driving strong sales growth and wider gross profit marginsgross profit marginsThe share of revenue left after subtracting cost of goods sold.View full glossary entry. However, the stock price already reflects immense future optimism, trading at twenty times annual revenue while the company still posts accounting losses and interest rates remain high.
Key insights
- Patients receive repeat testing over many years, creating steady recurring revenuerecurring revenueRevenue expected to repeat under subscriptions, contracts, renewals, or recurring customer usage.View full glossary entry for laboratories.
- Enormous spending on clinical trials proves the test works, but delays true company profits.
- Expensive stock grants and legal disputes slowly dilute the shares owned by everyday investors.
Deep Dive
Prevailing market consensus treats Signatera as an unassailable clinical monopoly destined to capture the multi-billion-dollar oncology surveillance market. Sell-side research extrapolates 35% compound revenue expansion and eventual 70% gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry into perpetuity. Anchored by recent NCCN guideline milestones, the crowd prices secular dominance while blithely dismissing persistent GAAP losses, commercial insurer prior-authorization friction, and extreme valuation multiples in a 5% Treasury yield regime.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market consensus treats Signatera as an unassailable clinical monopoly destined to capture the multi-billion-dollar oncology surveillance market. Sell-side research extrapolates 35% compound revenue expansion and eventual 70% gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry into perpetuity. Anchored by recent NCCN guideline milestones, the crowd prices secular dominance while blithely dismissing persistent GAAP losses, commercial insurer prior-authorization friction, and extreme valuation multiples in a 5% Treasury yield regime.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd overestimates the durability of Natera's valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry while misreading clinical momentum as owner cash flow. Diagnostics carry real physical processing costs, specimen logistics, and commercial payer friction. The market blind spot is assuming that 20 times sales can persist as revenue growth moderates from 38% toward 20% under high interest rates. Furthermore, trailing free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry is flattered by stock-based compensation add-backs and retrospective revenue true-ups, masking persistent statutory deficits.
Repricing Catalyst
What could make the market recognize and close that gap? Market repricing will be triggered when fiscal 2027 revenue guidance deceleration converges with structural R&D commitments exceeding $800 million and private payer claim audits. The first observable sign will be price-to-sales multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry following earnings releases where revenue beats fail to expand GAAP operating income, forcing growth allocators to re-underwrite shares on normalized cash yields rather than gross volume momentum.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Greed
- Volatility
- High Erratic
- Cycle position
- Overshoot
Reports agree that retail and momentum sentiment reflect greed and valuation overshoot. The core tension centers on whether guideline entrenchment justifies an extended premium multiple or whether high discount rates will enforce violent multiple normalization during 2027.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop of central bank policy rates near 4.00% and 10-year Treasury yields hovering near 5.0% acts as a severe valuation headwind. While underlying biological demand for oncology testing is highly inelastic and insulated from economic contractions, elevated discount rates rigorously penalize long-duration equities that lack substantial GAAP net profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across reports centers on valuation elasticity versus multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. Bullish views argue that monopolistic clinical guideline capture, Japanese commercialization, and companion diagnostic royalties justify an enduring premium valuation multiple near twelve to fifteen times sales. Conversely, value and macro perspectives demonstrate that in a 5% Treasury yield regime, trading at twenty times revenue with persistent GAAP losses mathematically necessitates multiple contraction toward single-digit sales ratios. Resolving this tension requires observing whether upcoming quarterly reports achieve genuine GAAP operating profitability without relying on retrospective revenue true-up adjustments.
Base-Case Forces
Event Risk ScoreVery High82/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Signatera oncology standard-of-care entrenchment | Competitive Positioning | +34% | +58% | Signatera's tumor-informed ctDNA assay has established an extensive clinical validation moat, processing nearly 300,000 quarterly oncology tests with 57% year-over-year volume growth. NCCN guideline inclusions drive oncologist habituation and severe switching costsswitching costsFinancial, operational, technical, contractual, or learning costs incurred when changing products or providers.View full glossary entry, converting episodic testing into longitudinal surveillance regimens that compound high-margin recurring test volume across solid tumors. |
| Medicare MolDX coverage indication expansion | Regulatory | +27% | +45% | Progressive MolDX local coverage determinations across bladder, breast, colorectal, and lung cancers systematically transform uncompensated tests into paid accessions. Medicare coverage solidifies baseline pricing near $1,275 per test and accelerates average selling prices, lowering bad-debt provisions and expanding gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry toward management's 70% long-term target. |
| Sequencing automation and laboratory scale | Operational Efficiency | +22% | +42% | Scaling annualized test accessions beyond four million units unlocks volume reagent discounts and amortizes automated high-throughput sequencer depreciation. Gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry advanced from 45.5% in 2023 to nearly 65% in 2026. This unit-economic operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry generates expanding gross profits that provide the foundation for eventual GAAP operating profitability. |
| Biopharma companion diagnostic partnership monetization | Innovation And Product | +17% | +27% | Pharmaceutical sponsors increasingly mandate Signatera endpoints in registrational oncology trials to stratify patients and track therapy efficacy. Hundreds of biopharma partnerships deliver high-margin contracted research revenues and upfront milestones without commercial payer friction, positioning the company for lucrative long-term companion diagnostic royalties upon novel drug approvals. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| High discount ratediscount rateThe rate used to convert future cash flows or values into present value.View full glossary entry terminal multipleterminal multipleValuation metric used to estimate the value of a company beyond the explicit forecast period.View full glossary entry compression | Macroeconomic And Macrofinancial | -35% | -6.0% | Trading near twenty times trailing sales and twenty-nine times book valuebook valueThe net asset value of a company calculated as total assets minus total liabilities.View full glossary entry while sovereign yields touch 5.0% exposes the equity to severe duration drag. Mathematical capital costs penalize long-duration earnings streams, exerting relentless downward mechanical pressure on forward trading multiples regardless of operational test volume compounding. |
| Commercial payer prior-authorization friction | Regulatory | -18% | -25% | Private health insurers facing elevated medical loss ratios are aggressively enforcing prior-authorization barriers, medical necessity audits, and claim denials for serial surveillance. This resistance caps realized average selling prices, lengthens collection cycles, and forces higher administrative overhead to litigate claims appeals. |
| Intensifying tumor-naive liquid biopsy competition | Competitive Positioning | -16% | -21% | Rivals deploying plasma-only, tumor-naive assays avoid the logistical friction of surgical tissue retrieval. As competing platforms achieve regulatory milestones and secure Medicare coverage in colorectal cancer, competitive bidding for hospital contracts will intensify, threatening Natera's premium pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry and eroding incremental market share. |
| Relentless clinical research expenditure drain | Capital Allocation | -15% | -28% | Maintaining guideline supremacy requires continuous capital reinvestment, with research and development guided to $800-$900 million annually. Expensing prospective clinical trials and screening algorithms absorbs gross profit gains, leaving net margins negative and deferring sustainable GAAP earnings power well into future fiscal years. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Adverse Medicare MolDX reimbursement rate reduction | 27% | -42% | Federal healthcare authorities or MolDX contractors could implement a 25% to 35% reimbursement cut for multiplex molecular diagnostic panels under PAMA review by 2027. Because Medicare anchors commercial rates, a tariff reset would immediately contract top-line revenues, erase nascent free cash flowsfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, and trigger traumatic multiple de-rating. |
| Catastrophic multiplex PCR patent invalidation verdict | 23% | -42% | An adverse federal appellate court ruling overturning core patents covering Natera's target-enrichment or multiplex amplification chemistry would dissolve its primary legal barrier to entry. Generic diagnostic reference laboratories would rapidly commercialize copycat assays, precipitating immediate price wars and permanently impairing long-term corporate gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Universal pan-cancer NCCN Category 1 mandate | 32% | +42% | The National Comprehensive Cancer Network could formally establish Category 1 recommendations mandating routine serial ctDNA surveillance across all resected solid tumors by 2028. Triggered by multi-center overall survival readouts, this regulatory milestone would eliminate private payer denials, doubling reimbursed volume and expanding GAAP operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry past 20%. |
| Breakthrough early multi-cancer screening validation | 23% | +52% | Natera's early colorectal or multi-cancer detection blood assay could achieve superior sensitivity in pivotal clinical readouts by 2028, unlocking FDA premarket approval and Medicare coverage. Entering the asymptomatic screening market would expand the addressable population tenfold, creating a multi-billion-dollar recurring cash flow stream beyond oncology recurrence monitoring. |
Company Financial Analysis
Natera Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Natera is demonstrating explosive revenue growth, reaching $2.71 billion over the trailing twelve months and growing 38% year-over-year in the second quarter of 2026. This expansion is powered by surging demand for Signatera, with oncology testing volume jumping 57%. Underneath the headline sales, however, the business remains unprofitable on a GAAP basis, posting a trailing net loss of $192 million. While reported operating cash flow turned positive and free cash flow reached $71.7 million, this cash generation is heavily supported by non-cash stock compensation and prior-period collection adjustments rather than true operational profits. Investors must distinguish between rapid top-line expansion and sustainable owner earnings.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 2.3B | USD -208.2M | USD 109.1M |
| 2024 | USD 1.7B | USD -190.4M | USD 69.2M |
| 2023 | USD 1.1B | USD -434.8M | USD -286.2M |
| 2022 | USD 820.2M | USD -547.8M | USD -479.2M |
| 2021 | USD 625.5M | USD -471.7M | USD -376.3M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Gross profit margins have improved dramatically, surging from 45.5% in 2023 to 64.8% in 2025 and holding at 64.5% in mid-2026. This structural improvement reflects automated laboratory robotics, cheaper sequencing chemistry, and a favorable product mix shift toward higher-priced oncology surveillance assays. In contrast, operating profit margins remain underwater at negative 10.7% over the trailing twelve months. High commercial sales overhead and elevated clinical trial expenditures absorb the entire gross profit expansion. Until sales and research costs stabilize relative to revenue, gross margin gains will struggle to translate into positive bottom-line net income.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -309.9M | -13.4% | -9.0% |
| 2024 | USD -222.3M | -13.1% | -11.2% |
| 2023 | USD -446.2M | -41.2% | -40.2% |
| 2022 | USD -541M | -66.0% | -66.8% |
| 2021 | USD -468.2M | -74.8% | -75.4% |
Balance sheet and leverage
AI Review
Natera possesses a well-funded balance sheet with substantial liquidity. By mid-2026, the company held over $1.09 billion in cash, equivalents, and short-term investments against just $80.3 million in bank credit facility debt. With an exceptionally low debt-to-equity ratio of 0.13 and a current ratio of 3.39, the enterprise faces virtually zero near-term bankruptcy or debt refinancing risks. However, this cash reserve was built through historical equity share sales rather than accumulated operating profits. Additionally, an outstanding $292.5 million false-advertising legal judgment awarded to Guardant Health represents an off-balance-sheet commitment that could drain liquid reserves if court appeals fail.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 214.4M | USD 1.1B | USD 861.8M net cash | 3.39x |
| 2024 | USD 187.1M | USD 968.3M | USD 758.5M net cash | 4.00x |
| 2023 | USD 442M | USD 879M | USD 200.1M net cash | 4.10x |
| 2022 | USD 446.2M | USD 898.4M | USD 19.9M net cash | 3.90x |
| 2021 | USD 397.2M | USD 914.3M | USD 312.8M net debt | 4.99x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management maintains a lean physical footprint, spending only 4.6% of revenue on physical laboratory equipment and facilities in 2025. Instead of brick-and-mortar factories, the company commits massive capital to intangible research and clinical validation. Research and development spending climbed to $624 million in 2025 and is projected between $800 million and $900 million in 2026. This aggressive spending funds extensive prospective oncology trials and early cancer detection programs. While these outlays build an formidable scientific evidence moat that keeps competitors at bay, they consume nearly all gross profit gains and postpone meaningful corporate profits into the distant future.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 106.2M | USD 624.1M |
| 2024 | USD 66.4M | USD 404.1M |
| 2023 | USD 39.2M | USD 320.7M |
| 2022 | USD 47.7M | USD 316.4M |
| 2021 | USD 41M | USD 264.2M |
Quarterly Forecast Scenarios
Natera Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $325.06 | $349.34 | $376.78 | $750.26 | |
| $292.56 | $334.88 | $391.85 | $736.44 | |
| $278.33 | $340.44 | $403.60 | $743.40 | |
| $261.63 | $326.41 | $391.50 | $755.15 | |
| $270.94 | $329.44 | $411.07 | $776.22 | |
| $255.48 | $324.75 | $435.74 | $787.13 | |
| $242.71 | $331.24 | $448.81 | $802.83 | |
| $255.86 | $330.64 | $439.83 | $812.05 | |
| $240.51 | $330.40 | $457.42 | $839.18 | |
| $228.48 | $334.89 | $480.30 | $850.50 | |
| $233.05 | $342.81 | $494.70 | $872.39 | |
| $223.73 | $342.21 | $479.86 | $885.51 | |
| $212.54 | $348.61 | $499.06 | $909.56 | |
| $206.17 | $350.75 | $524.01 | $916.13 | |
| $210.29 | $357.99 | $539.73 | $936.51 | |
| $203.98 | $358.44 | $528.94 | $947.34 | |
| $195.82 | $364.38 | $544.80 | $969.59 | |
| $197.78 | $368.24 | $566.60 | $979.99 | |
| $191.85 | $375.20 | $577.93 | $999.60 | |
| $188.01 | $377.89 | $583.71 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The research consensus demonstrates strong agreement on operational execution: Signatera is entrenching itself as standard-of-care in oncology surveillance, driving 35-40% top-line growth and expanding gross margins toward 65%. However, evaluations sharply diverge on terminal equity value. The dominant pattern identifies a severe growth-valuation paradox, where paying nearly twenty times sales in a 5% interest rate environment leads to mechanical multiple compression that neutralizes volume gains. The strongest contrarian case emphasizes monopolistic guideline lock-in and companion diagnostic royalties, but it understates commercial payer resistance, ongoing research cash burn, and the $292.5 million false-advertising verdict under appeal. Allocations heavily favor reports demonstrating direct grounding in regulatory dockets and SEC filings, while downweighting unhedged momentum projections. Unresolved uncertainties include private insurer denial rates and the clinical trial readout for early cancer screening.
Universal Investor AI
The Polymath
GPT-6 AstraExhibits superior factual verification from regulatory dockets and clinical trial literature. It carefully evaluates companion diagnostic milestones against the ALTAIR trial limitations and accounts for share dilution realistically.
Universal Investor AI
The Polymath
Opus 5Demonstrates outstanding empirical rigor backed by primary SEC filings, breaking down Q2 2026 revenue true-ups, the Guardant litigation exposure, and MolDX submission mechanics with superior causal precision.
Michael Burry AI
The Vulture
Gemini 3.8 FlashProvides exceptional forensic scrutiny of insider monetization, share dilution, and cash flow adjustments. It accurately identifies that headline free cash flow is heavily reliant on stock-based compensation add-backs in a high-rate environment.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashRigorous macroeconomic grounding connects sovereign interest rates to duration-driven multiple compression. It properly models Signatera oncology volume compounding alongside margin expansion, though it slightly understates near-term revenue true-up adjustments.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashDelivers an incisive examination of institutional reimbursement dynamics, state biomarker legislative mandates, and intellectual property battles, properly tempering regulatory triumphs with impending commercial payer pushback.
Universal Investor AI
The Polymath
Gemini 3.8 FlashSolid cross-disciplinary analysis captures the core growth-valuation tension and capital expenditure dynamics well. However, it relies on generic multiple compression assumptions without fully integrating specific clinical trial catalysts and reimbursement timelines.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashOffers a detailed decomposition of operating costs and competitive entries from reference laboratories. Its scrutiny of revenue true-ups is sound, though the terminal valuation multiple discount is applied somewhat aggressively.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashPresents strong balance sheet scrutiny and owner-earnings logic, highlighting the disparity between enterprise value and cash yields. It somewhat underestimates the durability of physician switching costs in clinical oncology.
Universal Investor AI
The Polymath
Gemini 3.8 FlashIntegrates clinical evidence milestones and laboratory automation efficiencies into a balanced valuation model, properly incorporating the ongoing financial drag of heavy exploratory research programs.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashArticulates the biological demand stickiness and laboratory automation scaling effectively. However, its upside path assumes rapid early cancer screening approvals that face substantial clinical sensitivity hurdles.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashEffectively contrasts gross margin improvements against persistent operating deficits. It provides a prudent conservative framework, though its recovery scenario in out-years overlooks potential companion diagnostic milestone contributions.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashOffers compelling perspective on biological demand inelasticity and clinical utility barriers. It clearly identifies the risk of multiple compression, though its price timeline is somewhat rigid.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashProvides valuable insight into international expansion in Japan and guideline adoption, but downweights significant commercial payer friction, ongoing litigation liabilities, and macro discount-rate pressures, producing an overly optimistic valuation trajectory.
Elon Musk AI
The Visionary
Gemini 3.8 FlashHighlights the threat of blood-only tumor-naive assays and legal liabilities from the Guardant false advertising verdict, but its price path overstates downside velocity relative to sticky Medicare test volumes.
Research Provenance
References & Context
This Natera consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 76 deduplicated sources retained for this batch.
- 01Premarket Approval (PMA)accessdata.fda.gov
- 02supplement and further confirm the aforementioned pre-market analytical and clinical data, post-market studies are planned as summarized in Section XV, below.accessdata.fda.gov
- 03Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
- 04https://www.sec.gov/Archives/edgar/data/1604821/000160482126000015/ntra-20260630xex991.htm?utm_source=openaisec.gov
- 05Natera, Inc. - Form 10-Q - FY2026sec.gov
- 06NATERA, INC._December 31, 2025sec.gov
- 07ntra-20260630sec.gov
- 08User | times-online.com - Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercializationbusiness.times-online.com
- 09Guardant Health - Dennis Gongdennisgong.com
- 10Natera Inc (NTRA) (Q2 2026) Earnings Call Highlights: Record Volumes and Raised Guidance Signal ...finance.yahoo.com
- 11Natera Q2 Earnings Call Highlightsfinance.yahoo.com
- 12Natera Stock Has Excellent Technical ‘DNA’ as NTRA Sets a New All-Time Highfinance.yahoo.com
- 13Natera, Inc. Q2 2026 Earnings Call Summaryfinance.yahoo.com
- 14Natera Inc (NTRA) Stock Up 6.1% but GF Value Says Overvalued -- GF Score: 77/100gurufocus.com
- 15Natera Q2 2026 slides: record volumes drive 38% revenue growth By Investing.cominvesting.com
And 61 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.